Therefore, an explanation for the difference in health-related quality of life domains between insulin degludec and insulin glargine may lie with the decreased rates of hypoglycaemia observed for insulin degludec in head-to-head trials with insulin glargine—although further research is needed to confirm this hypothesis. Here, INS is linked to Hypoglycemia.